Screener / SEC EDGAR /CIK 0001704292 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Zai Lab Ltd ZLAB

Compare with peers Embed
FY2025 at a glance

Sales up 15.3%, free cash flow up to -$158.9M

XBRL, from each 10-K
RevenueStatements
$460.2M from $399.0M in FY2024
FY2016FY2025
Net incomeStatements
-$175.5M from -$257.1M in FY2024
FY2016FY2025
Free cash flowStatements
-$158.9M from -$220.5M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-0.16 from $-0.26 in FY2024
FY2016FY2025
Operating marginStatements
-49.9% from -70.7% in FY2024
FY2016FY2025
Total debtStatements
$204.5M from $131.7M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (39)
EPS (ttm)
-0.18
Sales (ttm)
441.7M
Net income (ttm)
-198.4M
Sales growth
+15.3%
EPS growth
-
Sales Q/Q
-6.8%
Free cash flow
-163.3M
Gross margin
53.4%
Oper. margin
-63.0%
Net margin
-44.9%
FCF margin
-37.0%
R&D / sales
48.0%
Dividend
-
Debt/Eq
0.45
Curr. ratio
2.04
Cash
549.7M
Op. cash flow (ttm)
-159.2M
EBITDA
-214.4M
EBITDA margin
-46.6%
Net debt
-297.3M
Quick ratio
1.86
Interest cover
-44.05
FCF after stock pay
-224.5M
Oper. margin low 5y
-485.1%
Stock pay / sales
14.3%
Shares out.
1.1B
Shares Y/Y
+10.7%
Book / share
0.50
Cash / share
0.49
Sales / share
0.39
Asset turnover
0.43
Inventory turns
2.55
Days sales out.
84
Sales 3Y CAGR
+28.9%
Sales 5Y CAGR
+56.5%
Employees
1,784
Sales / employee
248K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2018 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 460.2M +221.7% a year Net income -175.5M
FY2018 revenue 129K · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-21-062279 FY2018 net income -139.1M · NetIncomeLoss, 0001193125-21-062279 129K FY2018 FY2019 revenue 13.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-22-061312 FY2019 net income -195.1M · NetIncomeLoss, 0001193125-22-061312 13.0M FY2019 FY2020 revenue 49.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-23-005832 FY2020 net income -268.9M · NetIncomeLoss, 0001628280-23-005832 49.0M FY2020 FY2021 revenue 144.3M · Revenues, 0001628280-24-007235 FY2021 net income -704.5M · NetIncomeLoss, 0001628280-24-007235 144.3M FY2021 FY2022 revenue 215.0M · Revenues, 0001628280-25-008409 FY2022 net income -443.3M · NetIncomeLoss, 0001628280-25-008409 215.0M FY2022 FY2023 revenue 266.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001704292-26-000015 FY2023 net income -334.6M · NetIncomeLoss, 0001704292-26-000015 266.7M FY2023 FY2024 revenue 399.0M · Revenues, 0001704292-26-000015 FY2024 net income -257.1M · NetIncomeLoss, 0001704292-26-000015 399.0M FY2024 FY2025 revenue 460.2M · Revenues, 0001704292-26-000015 FY2025 net income -175.5M · NetIncomeLoss, 0001704292-26-000015 460.2M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2018 to FY2025 (7 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -15.4% a year FY2020 $1.51 to FY2025 $0.65, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$0.16$0.65-$0.15
Dec 31, 2024 -$0.26$0.85-$0.22
Dec 31, 2023 -$0.35$0.82-$0.21
Dec 31, 2022 -$0.46$1.09-$0.41
Dec 31, 2021 -$0.76$1.48-$0.61
Dec 31, 2020 -$0.35$1.51-$0.29
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.0B
  • − All liabilities $456.9M
  • = Net current asset value $562.4M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $715.5M
  • − Other intangible assets $76.1M
  • = Tangible book value $639.4M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

ZLAB against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+15.3%56th of 155 · median +10.5%
Net margin
-4.1%15.3%
-44.9%138th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-35.2%126th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-37.0%129th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.4531st of 108 · median 0.69
ZLAB and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
ZLAB Zai Lab Ltd$441.7M +15.3%53.4%-44.9%-35.2%-37.0%0.45
ADMA Adma Biologics, Inc.$519.2M +19.6%68.5%35.1%41.6%25.6%0.45
KRYS Krystal Biotech, Inc.$470.0M +33.9%-47.9%15.7%66.0%-
WGS GeneDx Holdings Corp.$460.8M +40.0%68.7%-24.1%-45.4%-22.0%0.61
TWST Twist Bioscience Corp$431.8M +20.3%52.0%-31.7%-30.7%-21.6%-
PRCT PROCEPT BioRobotics Corp$352.3M +37.2%64.7%-32.6%-34.9%-24.1%0.16
All 162 companies in the group

Where the $457.2M of revenue came from

by product, year to Dec 31, 2025

  • ZEJULA $189.0M · 41%
  • VYVGART / VYVGART Hytrulo $94.2M · 21%
  • NUZYRA $60.8M · 13%
  • OPTUNE $48.3M · 11%
  • QINLOCK $35.6M · 8%
  • Other $29.2M · 6%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -24.5% FY2020: -23.0% net income ÷ equity
Net margin -38.1% FY2020: -549.3% profit per $ of sales: -175.5M ÷ 460.2M
Asset turnover 0.39× FY2020: 0.04× sales per $ of assets: 460.2M ÷ 1.2B
Leverage 1.64× FY2020: 1.11× assets per $ of equity: 1.2B ÷ 715.5M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -44.9% vs 6.8%
  • Return on equity below 15%
    -35.2%
  • A profit in 0 of 8 years
Net margin, FY2018 to FY2025: -107810.1% to -38.1%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -44.0× interest expense
  • Debt smaller than equity
    Debt / equity 0.45 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 2.04
  • More cash than debt
    Net cash $307.3M
Debt / equity at each year end, FY2018 to FY2025: 0.01 to 0.29

Cash and shareholders

  • Free cash flow positive in 0 of 8 years
    −$158.9M last year
  • Share count up over 5 years
    +41.0%
Free cash flow, FY2018 to FY2025: -107.6M to -158.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

ZLAB's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue460.2M
FY2016: -FY2017: -FY2018: 129KFY2019: 13.0MFY2020: 49.0MFY2021: 144.3MFY2022: 215.0MFY2023: 266.7MFY2024: 399.0MFY2025: 460.2M FY2017FY2019FY2021FY2023FY2025
Net income-175.5M
FY2016: -37.5MFY2017: -50.4MFY2018: -139.1MFY2019: -195.1MFY2020: -268.9MFY2021: -704.5MFY2022: -443.3MFY2023: -334.6MFY2024: -257.1MFY2025: -175.5M FY2017FY2019FY2021FY2023FY2025
Free cash flow-158.9M
FY2016: -34.4MFY2017: -41.5MFY2018: -107.6MFY2019: -197.0MFY2020: -226.2MFY2021: -567.5MFY2022: -392.2MFY2023: -205.4MFY2024: -220.5MFY2025: -158.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-224.5M
FY2016: -39.3MFY2017: -51.4MFY2018: -119.8MFY2019: -217.3MFY2020: -251.0MFY2021: -608.2MFY2022: -453.5MFY2023: -285.0MFY2024: -291.2MFY2025: -224.5M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-0.16
FY2016: -3.97FY2017: -2.32FY2018: -2.64FY2019: -3.03FY2020: -0.35FY2021: -0.76FY2022: -0.46FY2023: -0.35FY2024: -0.26FY2025: -0.16 FY2017FY2019FY2021FY2023FY2025
Diluted shares1.1B
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: 776.7MFY2021: 929.9MFY2022: 958.1MFY2023: 966.4MFY2024: 989.5MFY2025: 1.1B FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
ZEJULA 189.0M41.1% +1.0%
VYVGART / VYVGART Hytrulo 94.2M20.5% +0.6%
NUZYRA 60.8M13.2% +40.8%
OPTUNE 48.3M10.5% +19.4%
QINLOCK 35.6M7.7% +23.5%
XACDURO 22.9M5.0% +593%
AUGTYRO 5.5M1.2% +409%
Other 717K0.2% -

10-K 0001704292-26-000015, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue--129K13.0M49.0M144.3M215.0M266.7M399.0M460.2M
Cost of revenue--43K3.7M16.7M52.2M74.0M95.8M147.1M190.5M
Gross profit--86K-------
R&D32.1M39.3M120.3M142.2M222.7M573.3M286.4M265.9M234.5M220.9M
SG&A6.4M12.0M21.6M70.2M111.3M218.8M259.0M281.6M298.7M277.6M
Operating income-38.5M-51.4M-141.8M-203.2M-301.8M-700.1M-404.4M-366.6M-282.1M-229.4M
Interest expense--40K293K181K0002.3M5.2M
Pretax income-37.5M-50.4M-139.1M-195.1M-268.9M-704.5M-443.3M-334.6M-257.1M-178.5M
Income tax-00000000-2.9M
Net income-37.5M-50.4M-139.1M-195.1M-268.9M-704.5M-443.3M-334.6M-257.1M-175.5M
EPS (diluted)-3.97-2.32-2.64-3.03-0.35-0.76-0.46-0.35-0.26-0.16
Diluted shares----776.7M929.9M958.1M966.4M989.5M1.1B
Depreciation & amortization198K548K1.6M3.8M4.6M6.5M8.2M9.0M11.9M15.0M
EBITDA-38.3M-50.8M-140.1M-199.4M-297.2M-693.6M-396.1M-357.5M-270.3M-214.4M
Gross margin--66.6%-------
Operating margin---109897.7%-1564.9%-616.4%-485.1%-188.0%-137.4%-70.7%-49.9%
Net margin---107810.1%-1502.3%-549.3%-488.2%-206.1%-125.5%-64.4%-38.1%
Revenue growth---+9966%+277%+195%+49.0%+24.0%+49.6%+15.3%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-32.2M-32.4M-97.5M-191.0M-216.1M-549.2M-367.6M-198.2M-214.9M-150.8M
Capital spending2.2M9.1M10.0M6.0M10.1M18.3M24.6M7.2M5.7M8.1M
Free cash flow-34.4M-41.5M-107.6M-197.0M-226.2M-567.5M-392.2M-205.4M-220.5M-158.9M
Stock-based pay (added back)4.9M9.9M12.2M20.3M24.8M40.7M61.3M79.6M70.7M65.6M
Free cash flow after stock pay-39.3M-51.4M-119.8M-217.3M-251.0M-608.2M-453.5M-285.0M-291.2M-224.5M
Investing cash flow-2.7M-10.4M-212.6M-14.9M-554.8M250.0M420.0M-10.8M-375.2M307.9M
Financing cash flow106.2M187.9M144.1M219.3M1.1B820.2M-1.7M-6.4M349.9M72.4M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)4.9M9.9M12.2M20.3M24.8M40.7M61.3M79.6M70.7M65.6M
Stock-based pay / revenue--9479.8%156.3%50.7%28.2%28.5%29.9%17.7%14.3%
Operating lease cost---3.2M4.5M6.3M8.8M8.7M8.8M9.3M
Operating lease cash paid---2.8M4.1M5.8M8.1M9.3M8.8M8.7M
Right-of-use assets--7.1M15.1M17.7M14.2M19.5M14.8M21.5M19.2M
Operating lease liabilities--7.0M15.3M18.6M15.5M20.4M15.2M21.8M19.7M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ZLAB/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.